• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Vanda Pharmaceuticals (VNDA)

Common Shares
Sell: $5.06|Buy: $5.15|Change: 0.08 (1.58%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

Address

2200 Pennsylvania Avenue North West
Suite 300 E
Washington
DC
USA
20037

Telephone

+1 202 7343428

Website

https://www.vandapharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Vanda Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-08T16:30:00
Vanda Pharmaceuticals Inc First Quarter Earnings Results for 20252025-05-08T00:00:00
Vanda Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20242025-02-07T16:30:00
Vanda Pharmaceuticals Inc Fourth Quarter Earnings Results for 20242025-02-07T00:00:00
Vanda Pharmaceuticals Inc Annual Report for 20242025-02-07T00:00:00
Vanda Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20242024-11-08T16:30:00
Vanda Pharmaceuticals Inc Third Quarter Earnings Results for 20242024-11-08T00:00:00
Vanda Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20242024-07-26T16:30:00
Vanda Pharmaceuticals Inc Second Quarter Earnings Results for 20242024-07-26T00:00:00
Vanda Pharmaceuticals Inc Annual General Meeting for 20242024-06-07T09:00:00
Vanda Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-05-08T16:30:00
Vanda Pharmaceuticals Inc First Quarter Earnings Result for 20242024-05-08T00:00:00

Previous key dates

NameKey Date
Vanda Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-05-08T16:30:00
Vanda Pharmaceuticals Inc First Quarter Earnings Result for 20242024-05-08T00:00:00
Vanda Pharmaceuticals Inc Annual Report for 20232024-02-08T00:00:00
Vanda Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20232024-02-07T16:30:00
Vanda Pharmaceuticals Inc Fourth Quarter Earnings Result for 20232024-02-07T00:00:00
Vanda Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20232023-11-08T16:30:00
Vanda Pharmaceuticals Inc Third Quarter Earnings Result for 20232023-11-08T00:00:00
Vanda Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20232023-07-27T16:30:00
Vanda Pharmaceuticals Inc Second Quarter Earnings Result for 20232023-07-27T00:00:00
Vanda Pharmaceuticals Inc Annual General Meeting for 20232023-06-08T09:00:00
Vanda Pharmaceuticals Inc First Quarter Earnings Conference Call for 20232023-05-03T16:30:00
Vanda Pharmaceuticals Inc First Quarter Earnings Result for 20232023-05-03T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.